Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Amortization of Deferred Charges (2020 - 2022)

Insight Molecular Diagnostics' Amortization of Deferred Charges history spans 3 years, with the latest figure at $1000.0 for Q3 2022.

  • For Q3 2022, Amortization of Deferred Charges fell 92.31% year-over-year to $1000.0; the TTM value through Dec 2022 reached $12000.0, down 78.57%, while the annual FY2022 figure was $12000.0, 78.57% down from the prior year.
  • Amortization of Deferred Charges for Q3 2022 was $1000.0 at Insight Molecular Diagnostics, down from $4000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $35000.0 in Q1 2020 and bottomed at $1000.0 in Q3 2022.
  • The 3-year median for Amortization of Deferred Charges is $14000.0 (2021), against an average of $15454.5.
  • The largest annual shift saw Amortization of Deferred Charges plummeted 36.36% in 2021 before it tumbled 92.31% in 2022.
  • A 3-year view of Amortization of Deferred Charges shows it stood at $22000.0 in 2020, then plummeted by 54.55% to $10000.0 in 2021, then plummeted by 90.0% to $1000.0 in 2022.
  • Per Business Quant, the three most recent readings for IMDX's Amortization of Deferred Charges are $1000.0 (Q3 2022), $4000.0 (Q2 2022), and $7000.0 (Q1 2022).